Eupraxia Pharmaceuticals Completes $63.2M Public Offering
Analysis based on 7 articles · First reported Feb 19, 2026 · Last updated Feb 20, 2026
The successful public offering by Eupraxia Pharmaceuticals, raising $63.2 million, is expected to have a positive impact on the biotechnology market, particularly for companies in the clinical-stage drug development sector. The increased capital allows Eupraxia Pharmaceuticals to accelerate its drug development pipeline, potentially bringing new treatments to market and signaling investor confidence in the sector.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, successfully completed a public offering of common shares and pre-funded warrants, generating gross proceeds of approximately $63.2 million. The offering included the full exercise of the underwriters' option to purchase additional shares. The company intends to use the net proceeds primarily for advancing EP-104GI for eosinophilic esophagitis, including preclinical studies, Phase 2 and Phase 3 clinical trials, manufacturing, and commercial development. Funds will also support clinical studies for EP-104GI in other gastrointestinal indications, research and development of pipeline candidates, business development, and general corporate purposes. Cantor Fitzgerald and LifeSci Capital served as joint book-running managers, with Bloom Burton & Co. and Craig-Hallum Capital Group as co-managers. This capital raise strengthens Eupraxia Pharmaceuticals' balance sheet, which already holds more cash than debt and has a strong current ratio. Analysts from Raymond James Financial and Cantor Fitzgerald have expressed confidence in the company's prospects, with price targets ranging from $11 to $19.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard